PCLAF — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL31460258	0.65	1/20
SCHEMBL28397302	0.50	1/20
SCHEMBL28406570	0.50	1/20
SCHEMBL28406574	0.50	1/20
SCHEMBL29114339	0.50	1/20
SCHEMBL30678591	0.50	1/20
SCHEMBL30678594	0.50	1/20
SCHEMBL21956349	0.50	1/20
SCHEMBL21956350	0.50	1/20
SCHEMBL21956799	0.50	1/20
SCHEMBL21956803	0.50	1/20
SCHEMBL21957069	0.50	1/20
SCHEMBL21957071	0.50	1/20
SCHEMBL28400721	0.50	1/20
SCHEMBL28400726	0.50	1/20
SCHEMBL30678646	0.50	1/20
SCHEMBL29748683	0.49	1/20
SCHEMBL24881714	0.49	1/20
SCHEMBL29908946	0.49	1/20
SCHEMBL29908948	0.49	1/20

Clinical trials — most relevant to PCLAF by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI	PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent	PHASE1	UNKNOWN
Tabectedin to Treat Children and Adolescents With Cancer	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Assessing Colonic Folate Absorption & Metabolism	nan	UNKNOWN
Comparison of Serum Trefoil Factor 3 in Patients With Gingivitis and Periodontitis After Scaling and Root Planing	nan	COMPLETED
Fetal Alcohol Spectrum Disorder-Is This a Ciliopathy?	nan	COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Comparative 2-D Tumor Analysis in Familial Gliomas	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PCLAF binder may also engage these)

Protein	Name	Similarity
Q5E9B2	—	1.000	Q5E9B2 →
Q6RIA2	—	1.000	Q6RIA2 →
Q9CQX4	—	0.998	Q9CQX4 →
Q6AZL2	—	0.982	Q6AZL2 →
Q5HZL4	—	0.980	Q5HZL4 →
Q9EQ28	—	0.958	Q9EQ28 →
Q9QXK2	—	0.956	Q9QXK2 →
POLD3	DNA polymerase delta subunit 3	0.956	landscape →
B0KYV5	—	0.954	B0KYV5 →
RAD18	E3 ubiquitin-protein ligase RAD18	0.954	landscape →
Q5ZK28	—	0.954	Q5ZK28 →
Q5RCV3	—	0.952	Q5RCV3 →
A0JPQ7	—	0.951	A0JPQ7 →
Q96RL1	—	0.951	Q96RL1 →
Q5M947	—	0.951	Q5M947 →
CDC25A	M-phase inducer phosphatase 1	0.951	landscape →
O88878	—	0.950	O88878 →
O60934	—	0.950	O60934 →
Q9R207	—	0.950	Q9R207 →
Q9NZJ0	—	0.950	Q9NZJ0 →
P84798	—	0.949	P84798 →
Q5ZJ97	—	0.949	Q5ZJ97 →
P49790	—	0.949	P49790 →
P24793	—	0.949	P24793 →
O88271	—	0.949	O88271 →
Q9PSI9	—	0.949	Q9PSI9 →
Q5REG6	—	0.949	Q5REG6 →
F1LR10	—	0.948	F1LR10 →
RRP1B	Ribosomal RNA processing protein 1 homolog B	0.948	landscape →
Q5RD75	—	0.948	Q5RD75 →